ERBB2 and neoplasm: In particular, the application of anti-HER2/neu therapy to pTa or pT1 tumours that are most likely to progress to pT2 disease, based upon the presence of increased HER2 copy number, polysomy 17 and increased HER2/neu protein overexpression might lower the rate of disease progression.